IMUNON Expands Scientific Advisory Board with the Addition of Dr. Sachet Shukla
2023年8月14日 - 9:30PM
IMUNON, Inc. (NASDAQ: IMNN), a
clinical-stage drug-development company focused on developing
non-viral DNA-mediated immunotherapy and next-generation vaccines,
announces the addition of Sachet A. Shukla, Ph.D. to the company’s
scientific advisory board (SAB). Dr. Shukla is Assistant Professor,
Department of Hematopoietic Biology and Malignancy (HBM), Division
of Cancer Medicine at The University of Texas MD Anderson Cancer
Center. He joins current advisory board members Dan H. Barouch,
M.D., Ph.D., John W. Shiver, Ph.D., and Luke D. Handke, Ph.D.
“We are honored to add Dr. Shukla to our
scientific advisory board and are grateful that a scientist of his
stature has chosen to work with IMUNON,” said Dr. Corinne Le Goff,
president and chief executive officer of IMUNON. “We are eager to
advance our FixPlas and IndiPlas modalities into universal and
personalized cancer vaccines and have begun preclinical work in
melanoma. Dr. Shukla will provide invaluable assistance as we
advance along the development pathway and into clinical
testing.”
Dr. Shukla is Assistant Professor, Department of
Immunology, Division of Basic Science Research at MD Anderson,
where he also serves as Computational Director of MD Anderson’s
ECLIPSE Moon Shot Research platform, and Director of HBM’s Cancer
Vaccine Program. He previously worked as Computational Lead
Scientist at the Dana-Farber Cancer Institute, which he joined in
2008. Dr. Shukla received his Ph.D. from Iowa State University in
Bioinformatics and Statistics.
Dr. Shukla’s research studies focus on
elucidating the role of the immune system in cancer biology and the
discovery of novel immunotherapeutic targets through development of
immunogenomic approaches. He developed a computational method
called Polysolver for accurate typing and mutation detection in the
highly polymorphic human leukocyte antigen (HLA) genes using
next-generation sequencing data to address errors in genomic
analysis of immune-related genes. He developed a computational
pipeline for the rational design of neoantigen-based vaccines that
has already been used in two first-in-man clinical trials at
Dana-Farber Cancer Institute. The neoantigen prediction pipeline,
in conjunction with the Polysolver tool, has also led to the
identification of immunological correlates of several biological
and clinical features in various tumor types. Dr. Shukla also
worked in delineating mechanisms of response and resistance to
immune therapies, particularly checkpoint blockade. His laboratory
at MD Anderson is focused on antigen discovery and development of
personalized immunotherapies. Dr. Shukla has authored more than 60
peer-reviewed publications and has been recognized as one of the
most highly cited researchers over the last decade as evidenced by
multiple publications ranking in the top 1% by citations.
About IMUNON
IMUNON is a fully integrated, clinical-stage
biotechnology company focused on advancing a portfolio of
innovative treatments that harness the body’s natural mechanisms to
generate safe, effective and durable responses across a broad array
of human diseases, constituting a differentiating approach from
conventional therapies. IMUNON is developing its non-viral DNA
technology across four modalities. The first modality, TheraPlasTM,
is developed for the coding of proteins and cytokines in the
treatment of solid tumors where an immunological approach is deemed
promising. The second modality, PlaCCine TM is developed for the
coding of viral antigens that can elicit a strong immunological
response. This technology may represent a promising platform for
the development of vaccines in infectious diseases. The third
modality, FixPlas TM, concerns the application of our DNA
technology to produce universal cancer vaccines, also called tumor
associated antigen cancer vaccines. The fourth modality, which is
in the discovery phase, IndiPlas TM, will focus on the development
of personalized cancer vaccines, or neoepitope cancer vaccines.
The Company’s lead clinical program, IMNN-001,
is a DNA-based immunotherapy for the localized treatment of
advanced ovarian cancer currently in Phase 2 development. IMNN-001
works by instructing the body to produce safe and durable levels of
powerful cancer-fighting molecules, such as interleukin-12 and
interferon gamma, at the tumor site. Additionally, the Company is
conducting IND-enabling preclinical studies for the development of
a COVID-19 booster vaccine: IMNN-101. The Company has also
initiated preclinical work to develop a Trp2 tumor associated
antigen cancer vaccine in melanoma: IMNN-201. We will continue to
leverage these modalities and to advance the technological frontier
of plasmid DNA to better serve patients with difficult-to-treat
conditions. For more information on IMUNON,
visit www.imunon.com.
Forward-Looking Statements
IMUNON wishes to inform readers that
forward-looking statements in this news release are made pursuant
to the “safe harbor” provisions of the Private Securities
Litigation Reform Act of 1995. Readers are cautioned that such
forward-looking statements involve risks and uncertainties
including, without limitation, unforeseen changes in the course of
research and development activities and in clinical trials; the
uncertainties of and difficulties in analyzing interim clinical
data; the significant expense, time and risk of failure of
conducting clinical trials; the need for IMUNON to evaluate its
future development plans; possible acquisitions or licenses of
other technologies, assets or businesses; possible actions by
customers, suppliers, competitors or regulatory authorities; and
other risks detailed from time to time in IMUNON’s periodic reports
and prospectuses filed with the Securities and Exchange Commission.
IMUNON assumes no obligation to update or supplement
forward-looking statements that become untrue because of subsequent
events, new information or otherwise.
Contacts:
IMUNON |
LHA Investor Relations |
Jeffrey
W. Church |
Kim
Sutton Golodetz |
Executive
Vice President, CFO |
212-838-3777 |
and
Corporate Secretary |
Kgolodetz@lhai.com |
609-482-2455 |
|
jchurch@imunon.com |
|
# # #
Imunon (NASDAQ:IMNN)
過去 株価チャート
から 4 2024 まで 5 2024
Imunon (NASDAQ:IMNN)
過去 株価チャート
から 5 2023 まで 5 2024